XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact
The Pharma Data
JANUARY 27, 2021
Each study is planned to be carried out over an approximately two-week period as an open label, randomized, crossover, two-period, two-sequence, single dose pilot study to assess the relative bioavailability of each product. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp.
52 
Let's personalize your content